UK pharmaceutical giant GlaxoSmithKline (GSK.US) announced on Wednesday (3rd) that it has rebuilt its partnership with German biotechnology company CureVac and will acquire control of multiple vaccines jointly developed by the two companies.

GSK will pay CureVac an upfront payment of €400 million and up to €1.05 billion more for development/regulatory and sales milestones.

The two companies have been collaborating since 2020 to develop multiple infectious disease vaccines using messenger ribonucleic acid technology (mRNA). Through this transaction, CureVac has sold multiple vaccine development projects and received an upfront payment to enhance its cash position and focus on cancer treatment.

GSK will continue to develop the newly acquired clinical Phase 2 influenza and COVID-19 vaccine projects, as well as Phase 1 or preliminary stages of bird flu vaccine projects.